Abstract:Recombinant albumin-drug genetic fusions are an effective technology to prolong the serum half-life of therapeutics that has resulted in marketed products. Indirect evidence suggests albumin fusions' long circulation is controlled by engagement with the cellular recycling neonatal Fc receptor (FcRn) in addition to reduced kidney filtration. In this work, we have used a panel of recombinant fusions, engineered with different human FcRn (hFcRn) affinity, including a novel high binding albumin variant (HBII), to directly define and importantly, control the intracellular mechanism as a half-life extension tuning method. mNeonGreen or mCherry fusion to the N-terminal of the recombinant human albumin (rHA) variants null-binder (rHA NB), wild-type (rHA WT), high-binder I (rHA HBI), and high-binder II (rHA HBII) did not generally interfere with hFcRn interaction determined by Biolayer Interferometry. Co-localisation of the albumins with endosomal, but not lysosomal, markers was shown by confocal microscopy for high, but not low, hFcRn binders in a human microvascular endothelial hFcRn overexpressing cell line (HMEC-1 FcRn) suggestive of endosomal compartmentalisation. Furthermore, a cellular recycling assay revealed increased recycling of albumin fusions for the high binding variants (mNeonGreen WT; ~1, mNeonGreen HBI; 5.26-fold higher, and mNeonGreen HBII; 5.77-fold higher) in the hFcRn overexpressing cell line. In vivo experiments demonstrated a direct in vitro recycling/in vivo half-life correlation with a longer circulation for the mCherry fusions engineered with high hFcRn affinity that was highest with the HBII variant of 30.1 h compared to 18.2 h for the mCherry WT. This work gives the first direct evidence for an FcRn-driven endosomal cellular recycling pathway for recombinant albumin fusions that correlates with half-life extension controlled by the affinity to hFcRn; promoting a versatile method to tune the pharmacokinetics of albumin fusion-based therapeutics not met by current technologies.

Prediction of Half-Life Extension of Peptides via Serum Albumin Binding: Current Challenges

Development of a predictive algorithm for the efficacy of half-life extension strategies

Albumin-binding as a universal strategy for half-life extension

Albumin-based potential drugs: focus on half-life extension and nanoparticle preparation

Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins

Half-life extended biotherapeutics

Serum albumin-binding VH Hs with variable pH sensitivities enable tailored half-life extension of biologics

Understanding the Half-Life Extension of Intravitreally Administered Antibodies Binding to Ocular Albumin

Half-life extension using serum albumin-binding DARPin® domains

New Directions for Half-Life Extension of Protein Therapeutics: the Rise of Antibody Fc Domains and Fragments

Screened peptides from one-bead one-compound technique extend half-life of peptide drugs in circulation through binding to albumin

An Albumin Sandwich Enhances in Vivo Circulation and Stability of Metabolically Labile Peptides

Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement

Strategies for extending the half-life of biotherapeutics: successes and complications

Albumin-based drug delivery: harnessing nature to cure disease

Half‐Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation

Multi-cavity molecular descriptor interconnections: Enhanced protocol for prediction of serum albumin drug binding

The Minimal Effect of Linker Length for Fatty Acid Conjugation to a Small Protein on the Serum Half-Life Extension

Protein Engineering Strategies for Improved Pharmacokinetics

Introducing Enzymatic Cleavage Features and Transfer Learning Realizes Accurate Peptide Half-Life Prediction Across Species and Organs.

Prediction of Protein Half-lives from Amino Acid Sequences by Protein Language Models